drugset / Trial / NCT00570778

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00570778

Phase 2 Completed 154 enrolled Novartis Pharmaceuticals
RandomizedCrossoverTriple-blindTreatment

Summary

This study will evaluate the safety and efficacy of QVA149 in patients with moderate to severe COPD.

Timeline

Start
2007-12
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycopyrrolate Small molecule 50 ug Inhaled
Comparator Indacaterol Other / unclassified 300 ug Inhaled
Comparator Indacaterol Other / unclassified 600 ug Inhaled